- Home
- YMAB vs DCTH Comparison
YMAB vs DCTH Comparison
Compare YMAB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- DCTH
- Stock Information
- Founded
- YMAB 2015
- DCTH 1988
- Country
- YMAB United States
- DCTH United States
- Employees
- YMAB N/A
- DCTH N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- YMAB Health Care
- DCTH Health Care
- Exchange
- YMAB Nasdaq
- DCTH Nasdaq
- Market Cap
- YMAB 386.7M
- DCTH 394.9M
- IPO Year
- YMAB 2018
- DCTH N/A
- Fundamental
- Price
- YMAB $8.57
- DCTH $11.00
- Analyst Decision
- YMAB Buy
- DCTH Strong Buy
- Analyst Count
- YMAB 10
- DCTH 4
- Target Price
- YMAB $13.91
- DCTH $24.50
- AVG Volume (30 Days)
- YMAB 2.2M
- DCTH 795.2K
- Earning Date
- YMAB 08-08-2025
- DCTH 08-06-2025
- Dividend Yield
- YMAB N/A
- DCTH N/A
- EPS Growth
- YMAB N/A
- DCTH N/A
- EPS
- YMAB N/A
- DCTH 0.06
- Revenue
- YMAB $85,385,000.00
- DCTH $70,240,000.00
- Revenue This Year
- YMAB N/A
- DCTH $159.22
- Revenue Next Year
- YMAB $13.97
- DCTH $41.22
- P/E Ratio
- YMAB N/A
- DCTH $195.71
- Revenue Growth
- YMAB N/A
- DCTH 491.35
- 52 Week Low
- YMAB $3.55
- DCTH $8.08
- 52 Week High
- YMAB $16.11
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- YMAB 81.31
- DCTH 49.75
- Support Level
- YMAB $8.50
- DCTH $10.65
- Resistance Level
- YMAB $8.56
- DCTH $11.32
- Average True Range (ATR)
- YMAB 0.02
- DCTH 0.43
- MACD
- YMAB -0.12
- DCTH 0.12
- Stochastic Oscillator
- YMAB 83.33
- DCTH 72.87
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.